03:37 AM EST, 11/03/2026 (MT Newswires) -- Allergy Therapeutics (AGY.L) will seek shareholder approval to delist its shares from the London stock exchange's AIM market and re-register as a private limited company. The British biotechnology company's board cited limited free float and lack of share liquidity, the costs and regulatory burden of maintaining the AIM listing, and the difficulty of raising equity at an acceptable valuation. Shareholders will decide on the proposal at an annual general meeting.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.